Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients.

doi:10.1371/journal.pone.0226853

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients.

PloS one - 1 Jan 2019

Papadopoulou Eirini, Tsoulos Nikolaos, Tsantikidi Katerina, Metaxa-Mariatou Vasiliki, Stamou Pinelopi Eleftheria, Kladi-Skandali Athina, Kapeni Evgenia, Tsaousis Georgios, Pentheroudakis George, Petrakis Dimitrios, Lampropoulou Dimitra Ioanna, Aravantinos Gerasimos, Varthalitis Ioannis, Kesisis George, Boukovinas Ioannis, Papakotoulas Pavlos, Katirtzoglou Nikolaos, Athanasiadis Elias, Stavridi Flora, Christodoulou Christos, Koumarianou Anna, Eralp Yeşim, Nasioulas George

Abstract excerpt

BACKGROUND: Analysis of circulating tumor nucleic acids in plasma of Non-Small Cell Lung Cancer (NSCLC) patients is the most widespread and documented form of "liquid biopsy" and provides real-time information on the molecular profile of the tumor without an invasive tissue biopsy. METHODS: Liquid biopsy analysis was requested by the referral physician in 121 NSCLC patients at diagnosis and was performed using a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Decision-Making

Share to Drug Resistance, Neoplasm

Share to Feasibility Studies

Share to Liquid Biopsy

Share to Neoplasm Recurrence, Local

Share to Precision Medicine

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 31860648
DOI: 10.1371/journal.pone.0226853
PMCID: PMC6924668

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients.PMID 31860648Read ↗

Next generation sequencing techniques in liquid biopsy: focus on non-small cell lung cancer patientsSemantic proximity Read ↗

An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer.Semantic proximity Read ↗

Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC).Semantic proximity Read ↗

Future Perspectives in Detecting EGFR and ALK Gene Alterations in Liquid Biopsies of Patients with NSCLC.Semantic proximity Read ↗

Liquid biopsy and tissue biopsy for the detection of EGFR mutations in patients with stage III non-small-cell lung cancer: an observational real-world study.Semantic proximity Read ↗

The emerging roles of NGS-based liquid biopsy in non-small cell lung cancerSemantic proximity Read ↗

Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer.Semantic proximity Read ↗

Implementation of Next Generation Sequencing-Based Liquid Biopsy for Clinical Molecular Diagnostics in Non-Small Cell Lung Cancer (NSCLC) PatientsSemantic proximity Read ↗

Comparative analysis of genomic profiles between tissue-based and plasma-based next-generation sequencing in patients with non-small cell lung cancer.Semantic proximity Read ↗

Analytical and Clinical Validation of a Highly Sensitive NGS-Based ctDNA Assay with Real-World Concordance in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Validation and comparison of two NGS assays for the detection of EGFR T790M resistance mutation in liquid biopsies of NSCLC patientsSemantic proximity Read ↗

NGS analysis on tumor tissue and cfDNA for genotype-directed therapy in metastatic NSCLC patients. Between hope and hype?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.